Expansion of CD133+ colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery

被引:112
|
作者
Fang, D. D. [1 ]
Kim, Y. J. [1 ]
Lee, C. N. [1 ]
Aggarwal, S. [1 ]
McKinnon, K. [1 ]
Mesmer, D. [1 ]
Norton, J. [1 ]
Birse, C. E. [1 ]
He, T. [1 ]
Ruben, S. M. [1 ]
Moore, P. A. [1 ]
机构
[1] Celera Inc, Dept Prot Therapeut, Rockville, MD 20850 USA
关键词
CSC; CD133; colon cancer; drug target; drug resistance; mass spectrometry; TUMOR-INITIATING CELLS; ACUTE MYELOID-LEUKEMIA; PANCREATIC-CANCER; BRAIN-TUMORS; CADHERIN EXPRESSION; COLORECTAL-CANCER; PROGENITOR CELLS; OVARIAN-CANCER; IDENTIFICATION; POPULATION;
D O I
10.1038/sj.bjc.6605610
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Despite earlier studies demonstrating in vitro propagation of solid tumour cancer stem cells (CSCs) as non-adherent tumour spheres, it remains controversial as to whether CSCs can be maintained in vitro. Additional validation of the CSC properties of tumour spheres would support their use as CSC models and provide an opportunity to discover additional CSC cell surface markers to aid in CSC detection and potential elimination. METHODS: Primary tumour cells isolated from 13 surgically resected colon tumour specimens were propagated using serum-free CSC-selective conditions. The CSC properties of long-term cultured tumour spheres were established and mass spectrometry-based proteomics performed. RESULTS: Freshly isolated CD133(+) colorectal cancer cells gave rise to long-term tumour sphere (or spheroids) cultures maintaining CD133 expression. These spheroid cells were able to self-renew and differentiate into adherent epithelial lineages and recapitulate the phenotype of the original tumour. Relative to their differentiated progeny, tumour spheroid cells were more resistant to the chemotherapeutic irinotecan. Finally, CD44, CD166, CD29, CEACAM5, cadherin 17, and biglycan were identified by mass spectrometry to be enriched in CD133(+) tumour spheroid cells. CONCLUSION: Our data suggest that ex vivo-expanded colon CSCs isolated from clinical specimens can be maintained in culture enabling the identification of CSC cell surface-associated proteins. British Journal of Cancer (2010) 102, 1265-1275. doi: 10.1038/sj.bjc.6605610 www.bjcancer.com Published online 23 March 2010 (C) 2010 Cancer Research UK
引用
收藏
页码:1265 / 1275
页数:11
相关论文
共 50 条
  • [1] Expansion of CD133+ colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery
    D D Fang
    Y J Kim
    C N Lee
    S Aggarwal
    K McKinnon
    D Mesmer
    J Norton
    C E Birse
    T He
    S M Ruben
    P A Moore
    British Journal of Cancer, 2010, 102 : 1265 - 1275
  • [2] CD133+/ABCC5+ cervical cancer cells exhibit cancer stem cell properties
    He, Lin
    Qian, Hengjun
    Seyiti, Ayinuer
    Yang, Chengshaoxiong
    Shi, Ning
    Chen, Chen
    Zhang, Pingxu
    Hou, Youxiang
    HELIYON, 2024, 10 (17)
  • [3] Hypoxia promotes stem-like properties of laryngeal cancer cell lines by increasing the CD133+ stem cell fraction
    Wu, Chun-Ping
    Du, Huai-Dong
    Gong, Hong-Li
    Li, Da-Wei
    Tao, Lei
    Tian, Jie
    Zhou, Liang
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 44 (05) : 1652 - 1660
  • [4] CD133+ cancer stem cells in lung cancer
    Wang, Shuang
    Xu, Zhen Ye
    Wang, Li Fang
    Su, Wan
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2013, 18 : 447 - 453
  • [5] MicroRNA-135a-induced formation of CD133+ subpopulation with cancer stem cell properties in cervical cancer
    Leung, Carmen O. N.
    Deng, Wen
    Ye, Tian-Min
    Ngan, Hextan Y. S.
    Tsao, Sai Wah
    Cheung, Annie N. Y.
    Ziru, Niu
    Yuen, Dominic C. K.
    Pang, Ronald T. K.
    Yeung, William S. B.
    CARCINOGENESIS, 2020, 41 (11) : 1592 - 1604
  • [6] Development of a panel of colon cancer cell lines with cancer stem cell properties: a tool for cancer biology and target discovery
    Roberts, Penny
    Young, Peter
    Smith, Doug
    Hooley, Jeff
    Li, Jonathan
    Chen, Francine
    Loo, Deryk
    Mather, Jennie
    Moore, Paul A.
    CANCER RESEARCH, 2011, 71
  • [7] Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer
    Wang, Qi
    Chen, Zhi-Guo
    Du, Chang-Zheng
    Wang, Hong-Wei
    Yan, Li
    Gu, Jin
    HISTOPATHOLOGY, 2009, 55 (03) : 284 - 293
  • [8] CD133+ and CD133- Cancer stem cells in glioblastoma
    Beier, D.
    Hau, P.
    Proescholdt, M.
    Lohmeier, A.
    Aigner, L.
    Brawanski, A.
    Bogdahn, U.
    Beier, C. P.
    NEURO-ONCOLOGY, 2006, 8 (04) : 317 - 317
  • [9] Inhibition of Midkine Suppresses Prostate Cancer CD133+ Stem Cell Growth and Migration
    Erdogan, Suat
    Doganlar, Zeynep B.
    Doganlar, Oguzhan
    Turkekul, Kader
    Serttas, Riza
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2017, 354 (03): : 299 - 309
  • [10] Cancer stem cell marker CD133 attenuates colon cancer cell death induced by serum deprivation
    Mori, Yusuke
    Tatsumi, Yasutoshi
    Shimozato, Osamu
    CANCER SCIENCE, 2018, 109 : 1254 - 1254